Scholarlink

Abstract <p><i>Streptococcus suis</i> serotype 2 is a significant zoonotic pathogen that poses a serious threat to the health of humans and various animals. Ribosomal protein S1 (RPSA), acting as a key virulence factor, mediates SS2 adhesion to host cells and facilitates its penetration of the blood–brain barrier. In this study, we expressed the SS2 RPSA recombinant protein and used it to immunize BALB/c mice. Through screening, we obtained a high-affinity hybridoma clone and produced a specific anti-RPSA monoclonal antibody (designated mAb-RPSA-5E2). We found that mAb-RPSA-5E2 exhibited potent antibacterial activity, significantly inhibiting the proliferation of SS2 in vitro. In SS2-challenged mice, treatment with mAb-RPSA-5E2 significantly reduced mortality and alleviated pathological damage in the lung and brain tissues. Furthermore, evaluating the immunoprotective effect of the SS2-RPSA protein as a subunit vaccine revealed that this vaccine provided good protection against SS2 infection. These findings indicate that RPSA is a promising candidate target for developing SS2 subunit vaccines and targeted therapeutic biologics.</p> Key points <p>• <i>The SS2 RPSA monoclonal antibody can inhibit the proliferation of SS2 in vitro.</i></p> <p>• <i>The SS2 RPSA monoclonal antibody can reduce the mortality rates of mice.</i></p> <p>• <i>The SS2-RPSA subunit vaccine provides significant immunoprotective effects in mice.</i></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ribosomal protein RPSA is a promising target for the prevention of Streptococcus suis serotype 2

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Xiao Liu,
  • Bo Peng,
  • Fang Lv,
  • Guangyuan Wen,
  • Sijia Jin,
  • Dan Wang,
  • Jianwu Zhang,
  • Yunpeng Fan,
  • Yupeng Yin,
  • Shuqi Xiao

摘要

Abstract

Streptococcus suis serotype 2 is a significant zoonotic pathogen that poses a serious threat to the health of humans and various animals. Ribosomal protein S1 (RPSA), acting as a key virulence factor, mediates SS2 adhesion to host cells and facilitates its penetration of the blood–brain barrier. In this study, we expressed the SS2 RPSA recombinant protein and used it to immunize BALB/c mice. Through screening, we obtained a high-affinity hybridoma clone and produced a specific anti-RPSA monoclonal antibody (designated mAb-RPSA-5E2). We found that mAb-RPSA-5E2 exhibited potent antibacterial activity, significantly inhibiting the proliferation of SS2 in vitro. In SS2-challenged mice, treatment with mAb-RPSA-5E2 significantly reduced mortality and alleviated pathological damage in the lung and brain tissues. Furthermore, evaluating the immunoprotective effect of the SS2-RPSA protein as a subunit vaccine revealed that this vaccine provided good protection against SS2 infection. These findings indicate that RPSA is a promising candidate target for developing SS2 subunit vaccines and targeted therapeutic biologics.

Key points

• The SS2 RPSA monoclonal antibody can inhibit the proliferation of SS2 in vitro.

• The SS2 RPSA monoclonal antibody can reduce the mortality rates of mice.

• The SS2-RPSA subunit vaccine provides significant immunoprotective effects in mice.